Further in‐depth examinations should be undertaken to verify whether these findings can be confirmed in a larger older population and to determine whether therapeutic measures targeting NGAL balance would be helpful in delaying the progression of CKD and clinical complications, such as anemia and hypoalbuminemia. This evidence concerns the gene LCN2 and Hypoalbuminemia.